Steven Jay Isakoff MD PhD

Breast Cancer

Assistant Professor in Medicine, Massachusetts General Hospital

55 Fruit StYawkey 9ABoston, MA 02114
Phone+1 617-726-6500
Fax+1 617-643-0589

Dr. Isakoff is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Isakoff's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2006
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2002
New York University School of MedicineClass of 2000, MD, PhD
Princeton UniversityAB, Molecular Biology, Cum Laude, 1987 - 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2016-2017

Clinical Trials

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
COMPLETED
PHASE2
TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer
COMPLETED
NA
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
COMPLETED
PHASE2

Publications & Presentations

PubMed

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.
Dejan Juric, Kazi N Islam, Ioanna-Maria Gkotinakou, Alice Zheng, Hanjun Lee
Cancer Research. 2026-07-02
1 citations
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, o...
Seth A Wander, Maxwell R Lloyd, Jennifer C Keenan, Elizabeth C Scott, Andrzej Niemierko
The Lancet. Oncology. 2026-05-01
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.
Bogang Wu, Win Thant, Elena Bitman, Ting Liu, Jie Liu
Journal for Immunotherapy of Cancer. 2026-04-03

Press Mentions

Study Sparks Debate Over Annual Breast Cancer ScreeningDecember 15th, 2025
When to Get First Mammogram? Doctor Explains Latest AdviceMay 12th, 2023
Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-Negative, BRCA-Mutated Breast CancerAugust 10th, 2022